Beijing Xi'nuoyin Biotech Co, established in April 2021 with a registered capital of 40 million yuan, is located within the Beijing Free Trade Zone Innovation Service Center and covers an area of 6,300 square meters. It is a wholly-owned subsidiary of Beijing SINOGENE Biotech Co.
The company has developed and established a large animal gene editing technology platform, along with supporting experimental animal centers and animal experimental conditions, to promote the industrialization and application of gene-edited model animals in the field of innovative drug development such as gene therapy and cell therapy.
In addition, the company has collaborated with several high-level scientific research and medical institutions, resulting in the publication of international papers with an impact factor of over 100.